IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 951-975 out of 1269.

<< < 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 > >>

Public Release: 1-Jul-2014
Cancer Research
The inhibition of a protein opens the door to the treatment of pancreatic cancer
Researchers from IMIM have identified a new protein, galectin-1, as a possible therapeutic target for pancreatic cancer. For the first time they have demonstrated the effects of the inhibition of this protein in mice suffering this type of cancer and the results showed an increase in survival of 20%. The work further suggests that it could be a therapeutic target with no adverse effects.

Contact: Marta Calsina
IMIM (Hospital del Mar Medical Research Institute)

Public Release: 1-Jul-2014
Drug everolimus does not improve overall survival in patients with advanced liver cancer
Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA.

Contact: Katie Marquedant
The JAMA Network Journals

Public Release: 1-Jul-2014
Clinical Cancer Research
New approach identifies cancer mutations as targets of effective melanoma immunotherapy
A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy. This new approach may help develop more effective cancer immunotherapies, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
NIH/National Cancer Institute, Adelson Medical Research Foundation, Milstein Family Foundation, European Research Council

Contact: Jeremy Moore
American Association for Cancer Research

Public Release: 1-Jul-2014
Journal of the National Cancer Institute
Medicare-backed breast cancer screenings skyrocket, but do patients benefit?
Breast cancer screening costs for Medicare patients skyrocketed between 2001 and 2009, but the increase did not lead to earlier detection of new breast cancer cases, according to a study published by Yale School of Medicine researchers in the July 1 Journal of the National Cancer Institute.
NIH/National Cancer Institute, P30 Cancer Center Support Grant

Contact: Karen N. Peart
Yale University

Public Release: 30-Jun-2014
Journal of Leukocyte Biology
Is the next 'new' cancer drug already in your medicine cabinet?
The same types of drugs that help reduce watery eyes and runny noses during allergy season might also help ward off tumors too. A new research report appearing in the July 2014 issue of the Journal of Leukocyte Biology suggests that antihistamines may have significant anti-cancer properties as they interfere with the function of a type of cell that is known to reduce the body's ability to fight tumors.

Contact: Cody Mooneyhan
Federation of American Societies for Experimental Biology

Public Release: 30-Jun-2014
FASEB Journal
Stem cells may be more widespread and with greater potential than previously believed
With the plethora of research and published studies on stem cells over the last decade, many would say that the definition of stem cells is well established and commonly agreed upon. However, a new review article appearing in the July 2014 issue of The FASEB Journal, suggests that scientists have only scratched the surface of understanding the nature, physiology and location of these cells.

Contact: Cody Mooneyhan
Federation of American Societies for Experimental Biology

Public Release: 30-Jun-2014
Nature Cell Biology
A key component of cell division comes to light
The in vivo visualization and monitoring of the starting points of microtubules -- filaments responsible for organising the mitotic spindle -- provides novel insight into the dynamic architecture of this structure. The findings will also contribute to understanding how the mitotic spindle is perturbed by drugs that target microtubules and that are used in chemotherapy.

Contact: Sònia Armengou
Institute for Research in Biomedicine (IRB Barcelona)

Public Release: 30-Jun-2014
Proceedings of the National Academy of Sciences
Scientists engineer nanoparticles to prevent bone cancer, strengthen bones
A research collaboration between Brigham and Women's Hospital and Dana-Farber Cancer Institute has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent bone cancer progression.
National Institutes of Health

Contact: Marjorie Montemayor-Quellenberg
Brigham and Women's Hospital

Public Release: 30-Jun-2014
Journal of Clinical Oncology
HIV-positive people with early-stage cancer up to 4 times more likely to go untreated for cancer
HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine's Abramson Cancer Center and the National Cancer Institute published online ahead of print in the Journal of Clinical Oncology.
NIH/National Cancer Institute

Contact: Steve Graff
University of Pennsylvania School of Medicine

Public Release: 30-Jun-2014
Annals of Internal Medicine
New research study shows huge savings for health care
Recently published findings in Annals of Internal Medicine by Steven Lipshultz, M.D., Wayne State University professor and chair of pediatrics and pediatrician-in-chief at the Children's Hospital of Michigan, part of the Detroit Medical Center, and colleagues could help to reduce health care charges while also protecting childhood cancer survivors from heart ailments caused by drug therapy.
Lance Armstrong Foundation, NIH/National Cancer Institute

Contact: Julie O'Connor
Wayne State University - Office of the Vice President for Research

Public Release: 30-Jun-2014
Journal of Alternative and Complementary Medicine
St. John's wort can cause dangerous interactions with many common medications
St. John's wort is the most frequently used complementary and alternative medicine treatment in the US for depression and similar psychiatric disorders. The many commonly prescribed medications that St. John's wort can interact with -- sometimes with serious consequences such as serotonin syndrome or heart disease -- are reviewed in the Journal of Alternative and Complementary Medicine.

Contact: Kathryn Ruehle
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 30-Jun-2014
Journal of American College of Surgeons
Surgical treatment for metastatic melanoma of the liver increases overall survival
Surgical resection markedly improves survival among metastatic melanoma patients whose disease is isolated to a few areas in the liver, according to new study findings published in the July issue of the Journal of the American College of Surgeons.
National Cancer Institute, Dr Miriam & Sheldon G Adelson Medical Research Foundation

Contact: Sally Garneski
American College of Surgeons

Public Release: 30-Jun-2014
Molecular & Cellular Proteomics
Moffitt researchers develop new way to combat drug resistance for melanoma patients
Moffitt Cancer Center researchers developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma. It involves using liquid chromatography-multiple reaction monitoring mass spectrometry to measure biomarkers or molecules in blood and tissue that indicates cancer is present. These measurements can help researchers determine if a patient is responding to treatment.

Contact: Kim Polacek
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 30-Jun-2014
Population and Development Review
New study from population and development review finds flaws in mortality projections
A new study by Population Council demographer John Bongaarts has found that mortality projections from most low-mortality countries are more pessimistic than they should be. Existing projections fail to recognize that fewer people smoke today than used to. As a result, there will be a future decline in smoking-related mortality. This suggests that with more people living longer, pension and health care costs in coming decades will likely be higher than previously estimated.

Contact: Erin Kiernon
Population Council

Public Release: 29-Jun-2014
Nature Photonics
Single-pixel 'multiplex' captures elusive terahertz images
In an effort that advances attempts to generate images using terahertz light waves, researchers from Boston College, Duke University and the University of New Mexico report in Nature Photonics that they've developing a single-pixel 'multiplex' device that uses boutique metamaterials to capture images in the terahertz realm, which scientists say could play a crucial role in future medical and security imaging initiatives.
Office of Naval Research, National Science Foundation, DOE/Sandia National Laboratories

Contact: Ed Hayward
Boston College

Public Release: 29-Jun-2014
Nature Genetics
A single gene separates aggressive and non-aggressive lymphatic system cancer
For a rare form of cancer called thymoma, researchers have discovered a single gene defining the difference between a fast-growing tumor requiring aggressive treatment and a slow-growing tumor that doesn't require extensive therapy.
NIH/National Cancer Institute

Contact: Karen Teber
Georgetown University Medical Center

Public Release: 29-Jun-2014
Nature Physics
Improved method for isotope enrichment could secure a vital global commodity
Researchers at The University of Texas at Austin have devised a new method for enriching a group of the world's most expensive chemical commodities, stable isotopes, which are vital to medical imaging and nuclear power, as reported this week in the journal Nature Physics. For many isotopes, the new method is cheaper than existing methods. For others, it is more environmentally friendly.
The University of Texas at Austin

Contact: Steve Franklin
University of Texas at Austin

Public Release: 28-Jun-2014
ESMO World Congress on Gastrointestinal Cancer 2014
Annals of Oncology
Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

Contact: ESMO Press Office
European Society for Medical Oncology

Public Release: 28-Jun-2014
ESMO World Congress on Gastrointestinal Cancer 2014
Annals of Oncology
Improved survival with TAS-102 in mets colorectal cancer refractory to standard therapies
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

Contact: ESMO Press Office
European Society for Medical Oncology

Public Release: 27-Jun-2014
European Journal of Cancer
Genetics dominant risk factor in common cancers
A study of individuals who have been adopted has identified genetics as the dominant risk factor in 'familial' breast, prostate and colorectal cancers.

Contact: Bengt Zöller
Lund University

Public Release: 27-Jun-2014
Pain Medicine
Colon cancer survivors are more likely to have pain in the back and abdomen
Researchers from the University of Granada have discovered that colon cancer survivors are more likely to suffer future lesions related with pain in the back and lower abdomen than healthy individuals of the same gender and age.

Contact: Manuel Arroyo-Morales
University of Granada

Public Release: 27-Jun-2014
Cancer Cell
CNIO researchers discover more than 40 melanoma-specific genes that determine aggressiveness
Researchers from the Spanish National Cancer Research Centre have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis.

Contact: Nuria Noriega
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 27-Jun-2014
Cell Reports
Some aggressive cancers may respond to anti-inflammatory drugs
New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis.
National Institutes of Health, US Department of Defense

Contact: Julia Evangelou Strait
Washington University School of Medicine

Public Release: 26-Jun-2014
General Hospital Psychiatry
Researchers conduct comprehensive review of treatments for depression in cancer patients
When depression co-exists with cancer, patients may be at an increased risk of death from cancer and from suicide. Antidepressants are commonly prescribed, but the evidence on their efficacy is mixed. The role of antidepressants in treating cancer-related depression has not been rigorously studied. To identify best practice for the treatment of depression in cancer, Dartmouth researchers completed a systematic review and meta-analysis of existing research.

Contact: Robin Dutcher
The Geisel School of Medicine at Dartmouth

Public Release: 26-Jun-2014
Scientists find potential new use for cancer drug in gene therapy for blood disorders
Scientists working to make gene therapy a reality have solved a major hurdle: bypassing a blood stem cell's natural defenses and insert disease-fighting genes into the cell's genome. In a study led by Associate Professor Bruce Torbett at The Scripps Research Institute, researchers report the drug rapamycin, commonly used to slow cancer growth and prevent organ rejection, enables delivery of a therapeutic dose of genes to blood stem cells while preserving stem cell function.
National Insitutes of Health, Canadian CIHR Doctoral Research Award, California HIV/AIDS Research Program, Center/AIDS Research

Contact: Mika Ono
Scripps Research Institute

Showing releases 951-975 out of 1269.

<< < 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 > >>

  Search News Releases